Results 241 to 250 of about 28,272 (264)

Sex and reproductive stage modify the effect of endogenous oestrogens on coronary atherosclerosis in rheumatoid arthritis. [PDF]

RMD Open
Karpouzas GA, Papotti B, Ormseth SR, Palumbo M, Hernandez E, Budoff MJ, Ronda N.   +6 more
europepmc   +1 more source

Evolocumab Added to Statin Is Associated With Intracranial Atherosclerotic Plaque Regression Compared With Statin Alone. [PDF]

J Am Heart Assoc
Hu X, Liu Y, Yuan W, Zhang Z, Li S, Cheng A, Yu Q, Guo H, Zou Y, Li M, Liu C, Xu Y, Xu W.   +12 more
europepmc   +1 more source

Demographic And Clinical Characteristics Of Patients Prescribed Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor Therapy And Patients Whose Current Lipid-Lowering Therapy Was Modified

, 2019
Baum SJ, Wade RL, P Xiang, J Arellano, Cerezo Olmos C, S Nunna, Chen CC, Carter CM, Desai NR   +8 more
openalex   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Natural Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Review

Combinatorial Chemistry & High Throughput Screening, 2023
Abstract: PCSK9 (proprotein convertase subtilisin/kexin type 9) is an enzyme that helps to reduce cardiovascular events. This clinical result is attributable primarily to the crucial involvement of PCSK9 in regulating the low-density lipoprotein cholesterol level.
Sonia Singh, Himanshu Sharma, Raghavan Ramankutty, Sarada Ramaswamy, Nitin Agrawal   +4 more
openaire   +2 more sources

Proprotein convertase subtilisin/kexin type 9 inhibition

Current Opinion in Lipidology, 2012
There are now ample data that demonstrate that inhibition of PCSK9 (proprotein convertase subtilisin/kexin type 9) can safely lower LDL cholesterol synergistically with statins. Considering that PCSK9 was first identified less than a decade ago, the last few years have shown rapid and remarkable advancements in our understanding and knowledge of the ...
David A, Marais, Dirk J, Blom, Francine, Petrides, Yann, Gouëffic, Gilles, Lambert   +4 more
openaire   +2 more sources

Proprotein convertase subtilisin/kexin type 9

Current Opinion in Cardiology, 2018
This review describes the pivotal role of genetic insights and technologies in the discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the rapid development of PCSK9 inhibitors - a revolutionary new class of lipid-lowering agents.PCSK9 was discovered as a the third gene implicated in familial hypercholesterolemia. Population genetics
Robert M, Stoekenbroek, John J P, Kastelein   +1 more
openaire   +2 more sources

Proprotein Convertase Subtilisin/Kexin-Type 9 and Lipid Metabolism

2020
Plasma levels of cholesterol, especially low-density lipoprotein cholesterol (LDL-C), are positively correlated with the risk of cardiovascular disease. Buildup of LDL in the intima promotes the formation of foam cells and consequently initiates atherosclerosis, one of the main underlying causes of cardiovascular disease. Hepatic LDL receptor (LDLR) is
Shoudong, Guo, Xiao-Dan, Xia, Hong-Mei, Gu, Da-Wei, Zhang   +3 more
openaire   +2 more sources

Real-World Outcomes of Proprotein Convertase Subtilisin Kexin-9 Inhibitor Use

Journal of Cardiovascular Pharmacology, 2023
Abstract: Although the proprotein convertase subtilisin kexin-9 inhibitors (PCSK9i) were shown to significantly lower low-density lipoprotein and reduce atherosclerotic cardiovascular disease events in clinical trials, there is a dearth of use data on these agents in real-world settings.
Olivia M. Kim, Tatyana K. Givens, Emily G. Tang, Jennifer J. Schimmer, Tanya Ramsey, Kayla Boyd, Thomas Delate   +6 more
openaire   +2 more sources

Potential of Proprotein Convertase Subtilisin/Kexin Type 9 Based Therapeutics

Current Atherosclerosis Reports, 2013
The link between proprotein convertase subtilisin/kexin type 9 (PCSK9) and cholesterol metabolism was established only in 2003 when genetic mapping and positional cloning in patients with autosomal dominant hypercholesterolemia in which linkage to the loci coding for the LDL receptor and apolipoprotein B had been excluded identified the genetic defect ...
Evan A, Stein, Gary D, Swergold
openaire   +2 more sources

Proprotein Convertase Subtilisin/kexin type 9 Inhibition in Cardiovascular Prevention

Current Pharmaceutical Design, 2018
Elevated levels of Low Density Lipoprotein cholesterol (LDL-C) are directly associated with increased risk for atherosclerotic cardiovascular and cerebrovascular events. Statins have been used to control serum LDLC and this has translated into reduction in cardiovascular and cerebrovascular events.
Ali, Ali, Pierluigi, Costanzo, Angela, Hoye   +2 more
openaire   +2 more sources